What is the regulatory status of Tesamorelin?

Tesamorelin regulatory status: Approved (Egrifta 2010 for HIV lipodystrophy) in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For metabolic and glycemic use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

How does Tesamorelin affect glycemic and metabolic markers?

Tesamorelin's metabolic effects depend on whether it engages the incretin-amylin axis directly or operates through inflammation, mitochondrial, or adiposity pathways. Effects on glycemic markers tend to be gradual and operate through metabolic flexibility, inflammation reduction, and adiposity changes. Baseline HbA1c, fasting insulin, and — ideally — CGM during the first cycle clarify individual response.

What route should I use for Tesamorelin?

Tesamorelin is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What are the safety considerations for Tesamorelin?

Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. For metabolic and glycemic use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Tesamorelin's ~30 min pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

How does Tesamorelin's half-life affect dosing?

Tesamorelin has a plasma half-life of ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily subq dosing at 1-2 mg per dose explains the typical onset timeline for metabolic and glycemic endpoints.

What class of compound is Tesamorelin?

Tesamorelin is classified as a Stabilised GHRH analogue. Within this class, alternative names and analogues include Egrifta, TH9507. The class-level pharmacology shapes both the clinical applications and the safety profile; the metabolic / endocrine literature treats Tesamorelin alongside its class peers when evaluating relative merits.

Home/ Compounds/ Tesamorelin

Tesamorelin

Metabolic

For metabolic-syndrome, type-2-diabetes-spectrum, and obesity-medicine indications, Tesamorelin is one component in a multi-layer protocol. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat.. CGM-tracked individual response in the first cycle, paired with adequate protein intake and resistance training, is the practical framework for evaluating whether Tesamorelin contributes meaningfully at the 1-2 mg 1x daily subq dose.

Metabolic / Endocrine Applications

Visceral Fat ReductionType 2 Diabetes ResearchCardiometabolic RiskLipid ProfileGlucose Regulation

Key Takeaways

Metabolic lens: Tesamorelin is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers.
Mechanism: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage.
Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle.
Metabolic dose: 1-2 mg 1x daily subq via subq.
Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.

Metabolic / Endocrine Mechanism

Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. The metabolic medicine framework evaluates Tesamorelin against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.

AMPK and mitochondrial signalling

Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Tesamorelin engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.

Weight management and the appetite circuit

Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.

Insulin signalling and glycemic effect

Tesamorelin's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.

Metabolic / Endocrine Applications

Glucose Regulation

Tesamorelin for glucose regulation is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Fatty Liver Research

In the metabolic syndrome population, Tesamorelin for fatty liver research produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.

Appetite Regulation

Where Tesamorelin is used for appetite regulation, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.

Visceral Fat Reduction

Tesamorelin for visceral fat reduction is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Metabolic focus	SubQ	1-2 mg	1x daily SubQ
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for Tesamorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Tesamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.

Tesamorelin + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Tesamorelin's mechanism in metabolic / endocrine protocols.
Tesamorelin + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Tesamorelin's mechanism in metabolic / endocrine protocols.
Tesamorelin + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Tesamorelin's mechanism in metabolic / endocrine protocols.
Tesamorelin + AOD-9604: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Pairs naturally with Tesamorelin's mechanism in metabolic / endocrine protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated.

Lens-specific safety considerations for metabolic / endocrine use of Tesamorelin: Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Tesamorelin for HIV-associated lipodystrophy

PMID 20581419

Supporting

Tesamorelin visceral fat reduction mechanism

PMID 24247738

Tesamorelin vs Related Peptides

Compound	Profile	Onset	Best For
Tesamorelin	Stabilised GHRH analogue	~30 min	Metabolic
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding
Cagrilintide	Long-acting amylin analogue	~7 days	A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone

Frequently Asked Questions

How does Tesamorelin affect glycemic control?

Tesamorelin's effect on glycemic markers depends on its primary mechanism. Direct incretin and amylin agonists produce rapid and substantial shifts in fasting glucose and post-prandial response; compounds engaging insulin sensitivity indirectly produce more gradual shifts. Baseline HbA1c and — ideally — a CGM in the first cycle clarifies the individual response.

What weight loss can I expect?

Tesamorelin-attributable weight loss varies substantially by compound class, baseline body composition, and dietary and activity context. Direct incretin agonists produce the largest effect sizes in current literature; other peptide classes contribute more modestly and primarily through metabolic flexibility and inflammation reduction. Total trajectory matters more than first-month results.

Is Tesamorelin appropriate alongside metformin or other diabetes medications?

Most peptide compounds are compatible with metformin and complementary to sulfonylurea or insulin therapy with appropriate dose adjustment. Users on sulfonylureas or insulin should have those doses re-evaluated when adding Tesamorelin to avoid hypoglycaemia. Metformin combinations are generally well-tolerated and frequently used in metabolic medicine clinics.

Will I regain weight after stopping Tesamorelin?

For most compounds in this class, partial weight regain after discontinuation is the typical pattern unless dietary and activity inputs have been fundamentally changed during the cycle. Metabolic-medicine practice increasingly frames peptide therapy as chronic rather than time-limited for weight management indications.

What is Tesamorelin?

Tesamorelin (also known as Egrifta / TH9507) is a 44-residue stabilised ghrh analogue with a molecular weight of 5135 Da and a plasma half-life of ~30 min. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. The compound is studied primarily in the metabolic / endocrine domain for the applications outlined above.

What should I look for in Tesamorelin sourcing and quality?

Acceptable Tesamorelin certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 5135 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a Tesamorelin Protocol

Alukard provides physician-supervised metabolic protocols with GMP-certified Tesamorelin and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get Protocol

Quick Facts

Molecular weight: 5135 Da
Sequence length: 44 aa
Half-life: ~30 min
WADA: Banned (S2)
FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Stack Partners

Semaglutide (GLP-1)

Cagrilintide

MOTS-c

AOD-9604

Research Note

All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Tesamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised metabolic protocols

Start Your Metabolic / Endocrine Protocol for Tesamorelin

Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised